|
Aug 12
|
United States Epilepsy Drugs Market Trends and Company Analysis Report 2025-2033 Featuring Eisai, UCB, H. Lundbeck, GW Pharmaceuticals, Abbott, Alkem Laboratories, Bausch Health, GSK
|
|
Aug 1
|
Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus
|
|
Jul 31
|
Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
|
|
Jul 31
|
Mycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON
|
|
Jul 30
|
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
|
|
Jul 30
|
New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
|
|
Jul 30
|
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
|
|
Jul 23
|
Epilepsy Drugs Market Growth Analysis, Forecast Trends and Outlook Report 2025-2034 | Demand for Generic Epilepsy Drugs Rises as Patent Expirations Fuel Market Growth
|
|
Jul 22
|
Lecanemab four-year efficacy and safety data to be presented at AAIC 2025
|
|
Jul 21
|
EISAI TO PRESENT FOUR-YEAR EFFICACY AND SAFETY DATA ON CONTINUOUS TREATMENT WITH LECANEMAB AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025
|
|
Jul 17
|
Elix Provides AI Drug Discovery Platform "Elix Discovery™" to Eisai
|